(Total Views: 114)
Posted On: 05/05/2017 2:51:43 PM
Post# of 2218

$ADMP profile in these pages, Adamis Pharmaceuticals (NASDAQ: ADMP) which currently sells for just under $4.50 a share and has a market capitalization of just south of $100 million. The company consists of three different parts.
First, the company bought a contract manufacturer just less than a year ago for $8 million in stock and another $5 million in assumed debt. This was a good deal as that part of the business had a $20 million annual revenue run rate and is already cash flow positive.
First, the company bought a contract manufacturer just less than a year ago for $8 million in stock and another $5 million in assumed debt. This was a good deal as that part of the business had a $20 million annual revenue run rate and is already cash flow positive.


Scroll down for more posts ▼